Nanodose Therapeutics, Inc. (the "Company") is headquartered in Albany, NY and is a privately held pharmaceutical company formed in 2016 as a spinout from Beech Tree Labs, Inc. The Company was founded with the goal to commercialize two pharmaceutical products that Beech Tree developed – a proprietary streptolysin O compound (“NanoSLO”) and a series of products built around NanoSLO.  Since that time, Nanodose Therapeutics has been strengthening our platform with significant advances through genomic testing, animal model evaluations, FDA feedback and preparation for formal patient clinical trials.

 

Our products involve such small doses that we believe they utilize cellular signaling in addition to or rather than agonist/antagonist cellular binding as often occurs in new pharmaceuticals.  They impact several medical conditions – typically those that involve disorders of the central nervous system – such as chronic traumatic brain injury, Alzheimer’s disease, stroke and others.
​

The Company’s leadership includes a number of current and former biotech CEOs and embodies over 150 years of combined experience in building successful enterprises.